What Picato Treats: Main Uses and Benefits

The medication is a targeted topical therapy for adults, focusing exclusively on the specific skin changes and lesions that result from cumulative sun damage over time. The gel is used to treat Actinic Keratosis (AK), which are flat, scaly growths caused by too much sun exposure.

---

This medicine is commonly used to address conditions presenting with rough, scaly patches of skin classified as premalignant lesions, namely Actinic Keratosis and solar keratoses. The therapy is used for managing symptomatic relief associated with lesion reduction of these visible and palpable abnormalities, which supports the overall management of this chronic, sun-induced condition in adults.

The medication is utilized for field-directed therapy, a clinical approach that helps address not only the visible lesions but also the surrounding area that harbors numerous subclinical, atypical cells. By treating the entire photo-damaged field, the approach contributes to easing the overall symptom load by lowering the total burden of sun damage and supports the reduction of future lesion development.

“The treatment is relevant for managing both visible and unseen sun-damaged cells, and may assist patients seeking symptomatic support.”

The treatment is characterized by a short duration for application. This brief period of application is used for managing lesion reduction and contributes to easing the symptom load in the treated field, offering a significant benefit by assisting with maintaining functional stability and supporting patients by offering a briefer active therapy phase.

Quick Fact: Relief for Sun-Damaged Skin The treatment is relevant in contexts marked by the presence of scaly, premalignant lesions and is applied when field-directed symptomatic support is appropriate.

Regulatory References

1. NIH MedlinePlus overview of Ingenol Mebutate

Picato is a treatment indicated for use only in adults (18 years and older) with Actinic Keratosis.

---

Absolute Contraindications

Use of this medicine is strictly forbidden (contraindicated) for any patient with a known hypersensitivity or severe allergic reaction to ingenol mebutate or any component of the formulation.

---

Population-Specific Restrictions

• Pediatric Patients: The safety and effectiveness of Picato have not been established in patients under 18 years of age.
• Pregnancy and Lactation: Use is preferable to avoid during pregnancy due to limited human data. During breastfeeding, no effects on the infant are anticipated, but the infant must avoid physical contact with the treated area for six hours after application.
• Skin Status: The medicine must not be administered until the skin is fully healed from any previous drug or surgical treatment in the area. It is also not for oral, ophthalmic (eye), or intravaginal use.
• Regulatory Status: The marketing authorization for Picato has been suspended in regions including the European Union and the United Kingdom due to regulatory concerns regarding a potential increased risk of non-melanoma skin cancer.

Interactions with other medicines and products

Interaction Profile Based on Regulatory Data

The interaction profile of Picato (ingenol mebutate) gel is primarily defined by the finding of negligible systemic absorption following topical application. Official regulatory documents indicate that systemic blood levels of the active ingredient and its metabolites are below the limit of quantification.

Consequently, no systemic drug–drug interactions are documented in regulatory prescribing information. The active substance is not reported to inhibit or induce major CYP enzymes or interact via systemic transporters. This regulatory conclusion extends to other substance categories: no specific interactions are documented with food, alcohol, or herbal products.

Official Regulatory Restrictions

While systemic interactions are absent, regulatory labels establish specific topical and administrative restrictions:

• Co-administration Restriction: The medication must not be mixed with other topical medications or lotions when applied to the same treatment area. This restriction is in place to mitigate potential localized pharmacodynamic effects.
• Timing Requirement: Application is not recommended until the skin is fully healed from any previous drug treatment or surgical procedure in the intended area. This is a mandatory condition for administration.

This structure confirms that the official constraints for Picato are solely limited to administrative and localized co-application rules, with no identified risk of systemic interaction with other medicines.

Picato, containing ingenol mebutate, exerts its effects via a dual pharmacodynamic mechanism involving direct cellular cytotoxicity and immune system modulation in targeted epidermal tissue.

Cellular Cytotoxicity

Ingenol mebutate functions as an agonist for the intracellular enzyme Protein Kinase C (PKC), specifically delta- and alpha-isoforms. Agonist binding to PKC initiates a cascade that leads to the activation of the PKC/MEK/ERK signaling pathway. This pathway modulation is associated with the rapid induction of mitochondrial dysfunction, including disruption of the mitochondrial membrane potential and subsequent mitochondrial swelling. Additionally, ingenol mebutate inhibits the mitochondrial carnitine-acylcarnitine translocase (SLC25A20), impairing fatty acid oxidation. These intracellular consequences converge to induce rapid, localized cellular necrosis in the targeted cell population.

---

Systemic Immunomodulation

The agent also induces a localized inflammatory response. The activation of PKC is coupled with the release of cytokines, which initiates the recruitment of innate immune cells, primarily neutrophils, to the application site. These infiltrating neutrophils contribute to the clearance of residual cells through cytotoxic mechanisms, including neutrophil-mediated antibody-dependent cellular cytotoxicity (ADCC), which modulates the system-level clearance of the affected tissue.

Administration Scope

Picato (ingenol mebutate) is a topical gel that is applied directly to the skin surface for a fixed, short-duration course. The route of administration is strictly cutaneous; the gel is not for use in the eyes, mouth, or other internal areas. The dosing regimen is area-specific, meaning the concentration of the gel and the number of treatment days change based on the body location.

Location
Face or Scalp
Trunk or Extremities

---

Dosing Schedule and Constraints

For lesions on the face or scalp, the 0.015% gel is applied once daily for three consecutive days. For lesions located on the trunk or extremities, the 0.05% gel is applied once daily for two consecutive days. Regardless of the strength, one single-use tube is designated for application over a contiguous treatment area no larger than approximately 25 cm^2.

The proper use protocol includes specific procedural constraints: the gel must be allowed to dry for 15 minutes after application, and the treated area must not be washed or touched for a six-hour period following application. Hands must be thoroughly washed immediately after applying the gel, and the treatment is only applied to skin that has fully healed from any prior procedures. The final assessment of the therapeutic outcome typically occurs approximately eight weeks after the course is completed. Use is not established in patients under 18 years of age.

Research evidence / Overview of studies for Picato

This section provides an objective overview of the clinical research and evidence base for ingenol mebutate gel, summarizing the types of studies performed and the specific outcomes and populations examined, in alignment with regulatory reviews.

---

Evidence for use in Actinic Keratosis

The research base for ingenol mebutate includes short-term, randomized controlled trials (RCTs). These studies were generally vehicle-controlled, meaning the medicine was compared against an inactive gel (placebo) to explore patterns related to the active ingredient. Research examined adult patients with Actinic Keratosis (AK) that was not severely thickened or overly raised.

Studies monitored a core outcome called the Complete Clearance Rate (CCR). This outcome reflects the percentage of patients who achieved a complete disappearance of all visible AK lesions within a specific treatment area, typically a 25 cm^2 patch of skin. This research explored short-term changes in lesion status, with the primary measurement being taken approximately eight weeks (Day 57) following the study treatment window. Findings describe patterns observed in the studies related to the resolution of lesions that was associated with the active gel when compared against the vehicle gel across the study populations.

The research also explored differences in outcomes based on where the lesions were located. Separate trials was studied for lesions on the face and scalp compared to those on the trunk and extremities. Studies monitored changes measured during the study period, which helps contextualize how lesion status evolved in the observed populations across different body sites.

---

Long-term studies and durability of outcomes

To gather more extensive data, researchers conducted observational extension studies. These studies monitored patients who had achieved initial lesion clearance in the short-term trials, tracking them for up to 12 months (one year). These long-term studies report how lesions evolved in the observed populations in the treated area and how often lesions may reappear.

Research so far indicates that the long-term clearance status is not fully established by the core RCTs. Long-term data derived from settings with varying lesion burdens are still emerging, and certainty remains low regarding sustained absence of lesions beyond the study periods.

---

What is still uncertain about the research

A key limitation is that comparative evidence is lacking. The core evidence base was studied for comparisons against a vehicle (placebo) gel. The limited availability of active comparator trials means the relative differences between ingenol mebutate and other existing treatments are not well characterized by the primary research.

Additionally, the follow-up durations were limited in the key clinical trials, with the primary measurement assessed at 57 days. The initial short-term nature of the measurement means that evidence is limited regarding the long-term status of the skin and recurrence rates after the one-year mark. Thus, long-term effects are not fully established, and evidence highlights what is known — and what is still uncertain — about the medicine's role in the broader management of Actinic Keratosis.

Key Studies & References Key clinical-trial evidence for ingenol mebutate gel - DermNet (Summarizing Phase 3 study design and 12-month follow-up data)

Common questions about Picato (FAQ)

Q: Is Picato the same type of medicine as 5-fluorouracil cream?

A: Picato (ingenol mebutate) and 5-fluorouracil (5-FU) are both topical prescription medicines used to treat actinic keratosis. While they have different mechanisms, regulatory documents classify Picato as a cytotoxic and antineoplastic agent. Official reviews of therapies for actinic keratosis often list both medicines as available treatment options.

Q: Is it normal for the treated area to look worse before it gets better with Picato?

A: Yes, it is common and expected for the treated area to develop intense, visible reactions. Official product information states that local skin reactions (LSRs), such as redness, peeling, crusting, swelling, and erosion, are Very Common. These reactions typically reach their peak severity up to one week after completing the treatment course before they begin to resolve naturally.

Q: Can I go out in the sun while using or soon after using Picato?

A: Regulatory warnings advise that excessive exposure to sunlight, including sunlamps and tanning beds, should be avoided or minimized during the treatment period. The label does not provide specific instructions regarding sun protection requirements after the treatment course is finished.

Q: Are there any specific cleansers or moisturizers I should avoid while using Picato?

A: Regulatory guidance strictly states that Picato gel must not be mixed with other topical medications or lotions when applied to the designated treatment area. This restriction is in place to manage how the medicine works on the skin in the treatment area.

Q: Can I use Picato if I'm already using other prescription skin products?

A: Official safety warnings indicate that administration is not recommended until the skin is fully healed from any previous drug treatment or surgical procedure in the intended area. This condition is established in regulatory documents for the administration of the medicine.

Q: Can I apply makeup or shave the treated area after the Picato application period?

A: The application protocol requires that the treated area is not washed or touched for a specific six-hour period following application. Official guidance cautions against accidental transfer, such as avoiding applying makeup immediately after the application, especially around the eyes.

Q: What should I do if the burning/pain from Picato becomes unbearable?

A: Pain and application site burning are listed in regulatory documents as Very Common expected reactions. If the pain or any other local skin reactions become severe, official guidance emphasizes the importance of promptly consulting a healthcare professional for further assessment.

Q: What does the research say about the recurrence rate of AK after Picato treatment?

A: Studies included in regulatory reviews show that while the medicine is effective at clearing lesions in the short term, lesions may reappear. Observational studies following patients who achieved initial clearance report that recurrence was seen in approximately 54% to 56% of those patients at the one-year mark, with the rate varying by body location.

Q: Is Picato a type of chemotherapy drug for the skin?

A: Yes, the active ingredient in Picato, ingenol mebutate, is formally classified by regulatory bodies as an Antineoplastic (chemotherapeutic) agent. It is categorized this way because its function is to cause the effective destruction and clearance of certain atypical skin cells in the area where it is applied.

Q: What happens if I accidentally get Picato on healthy skin?

A: Care should be taken to apply the gel only to the affected area. Accidental exposure to sensitive areas like the eyes or mouth/lips can cause serious adverse reactions. In the event of accidental exposure, especially to the eyes, regulatory information highlights the need for immediate flushing with water and contacting a healthcare professional.

Q: Is Picato safe for older patients, like those over 75?

A: Picato is indicated for use in adults (18 years and older). Clinical studies included a number of patients over 65 years old. Regulatory documents do not list any specific warnings related solely to advanced age within the adult population.

Q: Has Picato been studied in people with darker skin tones?

A: Regulatory documents indicate that clinical trials primarily enrolled individuals with lighter skin types (Fitzpatrick types I and II), which are the populations most commonly affected by actinic keratosis.

Q: Is Picato known to interact with common pain relievers like ibuprofen?

A: Due to the negligible amount of the active ingredient that enters the bloodstream after topical application, no systemic drug-drug interactions are documented in the official prescribing information. This conclusion extends to common oral medications, including pain relievers like ibuprofen and blood thinners.

Q: What are the long-term effects of using Picato?

A: A potential long-term effect identified in post-marketing reports and later regulatory reviews is an increased risk of developing Non-Melanoma Skin Cancer (NMSC) in the treated area. Official labeling advises that monitoring for the appearance of new skin lesions following treatment is an important measure to manage this risk.

Q: Does the healing time for side effects differ based on where Picato is applied?

A: The local skin reactions (LSRs) are expected on all treated areas, but the duration of resolution differs. Official information states that LSRs resolve more quickly on the face and scalp (typically within two weeks) than on the trunk and extremities (typically within four weeks).

Q: Is a tingling sensation a normal reaction after applying Picato?

A: Yes, a tingling sensation or numbness, referred to as paraesthesia, is reported in official product information. This is listed as an Uncommon side effect at the application site.

Q: Does Picato make you more sensitive to cold or heat in the treated area?

A: One of the side effects listed in the product information is a feeling of warmth at the application site. This is an Uncommon side effect.

Q: Are there any contraindications or warnings for people with a history of heart problems?

A: Since the active ingredient is minimally absorbed systemically, regulatory documents note no systemic warning regarding pre-existing heart conditions. No systemic drug interactions are documented in the official prescribing information.

Q: Does Picato interact with blood thinners?

A: Due to the negligible systemic absorption of the active ingredient after topical application, official prescribing information documents no systemic drug-drug interactions, including with common oral medications like blood thinners.

Q: Is scarring a reported side effect of Picato treatment?

A: Scarring is not listed as a common or uncommon adverse reaction in the regulatory documents. The local skin responses caused by the medicine are described as transient, expected to resolve fully within two to four weeks.

Q: How long after the treatment period does Picato continue to work?

A: The medicine's action involves both the rapid destruction of cells and the initiation of a localized inflammatory response which continues the clearance process over time. The full clinical effect of the medicine is not assessed until approximately eight weeks after the short treatment course is complete.

Q: Does Picato need special disposal instructions for the used tubes?

A: Yes. Patients are instructed to consult their pharmacist or local waste authority for guidance on the proper disposal of medicinal product waste according to local regulations. Unused or expired gel and used tubes must not be disposed of with ordinary household waste or poured into wastewater.

Storage and Disposal of Picato (ingenol mebutate) Gel

Picato gel must be stored under specific regulatory conditions to maintain product stability.

Required Storage and Handling

Storage Requirement	Detail
Temperature	Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
Freezing	Do not freeze the product.
Container	Keep in the original container until use.
Child Safety	Store out of the sight and reach of children.
Use Limits	Each tube is for single use only and must not be reused.

---

Disposal Requirements

To protect the environment, unused or expired Picato gel must not be thrown away with household waste or poured into wastewater. Patients are instructed to consult a pharmacist for guidance on the proper disposal of medicinal product waste according to local regulations.